Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lowered by Boston Trust Walden Corp

Boston Trust Walden Corp cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 485 shares of the pharmaceutical company’s stock after selling 125 shares during the period. Boston Trust Walden Corp’s holdings in Vertex Pharmaceuticals were worth $216,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd raised its position in shares of Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $32,000. American National Bank & Trust raised its position in shares of Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Vertex Pharmaceuticals during the first quarter worth $46,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $407.90 on Thursday. The business’s 50-day moving average price is $393.80 and its two-hundred day moving average price is $437.75. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The company has a market capitalization of $104.58 billion, a P/E ratio of 29.16 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the company posted ($12.83) earnings per share. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling

In other news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This trade represents a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

VRTX has been the topic of a number of recent analyst reports. Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. UBS Group set a $553.00 target price on Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price target for the company from $458.00 to $456.00 in a report on Thursday, September 25th. Finally, Evercore ISI lowered their price target on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $494.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.